New book by former FDA head explores the science behind GLP-1 weight loss drugs

A Former FDA Commissioner Writes About GLP-1s, and His Perspective Is Unique

This PBS NewsHour segment covers a new book by a former head of the FDA that examines the science, politics, and public health implications of GLP-1 weight loss drugs. Having someone with inside knowledge of the regulatory process write about these medications adds a layer of analysis that typical medical commentary cannot match. The segment is worth watching specifically for the policy perspective it provides alongside the science.

The former FDA head argues that GLP-1 drugs represent one of the most significant pharmaceutical developments in decades, for more than what they do medically, but for what they reveal about how we think about obesity. For most of modern medicine, obesity has been treated as a behavioral problem. Eat less, move more. The failure of that approach is written in the population-level data: obesity rates have climbed steadily for 40 years despite constant public health messaging about diet and exercise.

GLP-1 drugs, the argument goes, finally prove at scale that obesity has a strong biological component. When you give people a drug that modulates appetite hormones, they lose significant weight without heroic willpower. That does not mean lifestyle does not matter. It means biology was a bigger barrier than most people, including many doctors, wanted to admit. This reframing has implications for everything from insurance coverage to how physicians talk to patients about weight.

The Regulatory Story Behind the Drugs

The most interesting parts of the segment are the behind-the-scenes regulatory details. The former FDA head describes the approval process for semaglutide and tirzepatide, noting that the weight loss indications came after diabetes approvals. Ozempic was approved for diabetes in 2017. It took until 2021 for Wegovy (the same molecule, semaglutide, at a higher dose) to get approved specifically for weight management.

That four-year gap reflects the FDA traditional caution around weight loss drugs. The agency has been burned before. Fen-phen caused heart valve damage. Meridia increased cardiovascular risk. Belviq was pulled from the market over cancer concerns. Each failure made the FDA more conservative about approving weight loss medications, requiring longer trials and harder endpoints. GLP-1 drugs had to clear a higher bar than most drug classes, and they did.

The book apparently discusses the internal FDA debates about whether these drugs should require evidence of cardiovascular benefit, more than weight loss. The SELECT trial, which showed semaglutide reduced cardiovascular events by 20% in obese patients without diabetes, answered that question definitively. But the trial was not complete when the weight loss indication was initially approved, so the early approval was based on weight loss data alone with cardiovascular outcomes as a post-market commitment.

This kind of regulatory detail matters because it helps patients understand why the evidence base for these drugs is actually quite strong. They did not get a free pass through the approval process. They went through extensive testing, and the agencies that approved them had institutional reasons to be skeptical.

Public Health Implications That Go Beyond Individual Patients

The segment discusses the population-level impact of having effective obesity treatments available. If 40% of American adults are obese, and obesity is a major driver of type 2 diabetes, heart disease, certain cancers, and joint disease, then a drug class that reliably reduces weight has staggering public health potential. The former FDA head estimates that widespread use of GLP-1 drugs could prevent millions of cases of diabetes and hundreds of thousands of cardiovascular events over the next decade.

But there is a catch, and the book apparently does not shy away from it. At current prices, treating even a fraction of the eligible population would cost hundreds of billions of dollars annually. The US healthcare system, already the most expensive in the world, would need to absorb this cost somehow. Insurance companies, Medicare, and Medicaid are all grappling with how to handle coverage for a drug class that could theoretically be prescribed to 100 million Americans.

The supply issue is related. Novo Nordisk and Eli Lilly, the two companies behind the major GLP-1 drugs, have struggled to keep up with demand. Shortages have been ongoing since 2023. The book discusses what it would take to scale manufacturing to meet population-level demand, and the answer is a massive expansion of production capacity that is still years away.

The Compounding Pharmacy Debate

PBS covers the compounding controversy, which is one of the most contentious current topics around GLP-1 drugs. When branded versions were in shortage, the FDA allowed compounding pharmacies to produce versions of semaglutide and tirzepatide. These compounded versions cost a fraction of the branded price, typically $200-400 per month compared to $1,000+. Millions of patients accessed GLP-1 therapy through compounding for the first time.

The pharmaceutical companies have pushed back hard, arguing that compounded versions are inferior, potentially unsafe, and infringe on their patents. The former FDA head walks a careful line here, acknowledging both the legitimate quality concerns about compounding and the access problem that compounding was solving. He notes that the FDA shortage designations that enabled legal compounding are tied to supply availability, and as branded supply normalizes, the legal basis for compounding these drugs narrows.

This is not an abstract policy debate. It directly affects patients. Someone who has been losing weight on compounded semaglutide at $300 per month and who cannot afford $1,300 per month for branded Wegovy faces a real problem if compounded versions become unavailable. The book apparently argues for structural solutions, including price negotiation, expanded insurance coverage, and possibly accelerated generic timelines, rather than relying on the compounding workaround indefinitely.

What This Means If You Are Considering a GLP-1 Drug

The policy context matters for individual patients more than you might think. Here are the practical implications. If you are currently on a compounded GLP-1, pay attention to the regulatory space. The FDA could restrict compounding at any time if shortages are deemed resolved. Have a plan B that does not depend on continued access to compounded versions. Talk to your prescriber about what happens if your current source becomes unavailable.

If cost is a barrier to branded GLP-1 drugs, explore all available options. Manufacturer savings programs, insurance appeals, patient assistance programs, and state-level programs may reduce your out-of-pocket cost. Some patients have successfully appealed insurance denials by providing documentation of obesity-related comorbidities that make the medical necessity case stronger.

Understand that the long-term picture for GLP-1 access is likely to improve. Patents on semaglutide will eventually expire, opening the door to generic versions. Additional drugs in the class are in development, which will increase competition and likely reduce prices. Oral formulations (pill versions of semaglutide) are already in late-stage trials and could change the cost and convenience equation significantly.

The former FDA head ultimately views GLP-1 drugs as a positive development for public health, but one that requires systemic changes in pricing, access, and insurance coverage to achieve its full potential. That is a measured take, and it reflects the complexity of a drug class that is simultaneously a medical breakthrough and an economic challenge.

Questions for Your Doctor After Watching This

Ask about the regulatory status of whatever GLP-1 product you are being prescribed. Is it a branded FDA-approved product or a compounded version? Both can be appropriate, but you should know which you are getting and understand the implications for continuity of care. Ask about the evidence base for your specific indication. Weight loss and diabetes have the strongest data, but off-label uses are growing. Ask what monitoring schedule your doctor recommends and what metrics they will use to evaluate whether the drug is working for you. And ask about the exit plan. What happens if you stop? What does long-term maintenance look like? These are questions the former FDA head raises, and they deserve clear answers from your own physician.

The SELECT Trial and Its Impact on GLP-1 Drug Approvals

The SELECT trial, published in the New England Journal of Medicine in 2023, was the study that transformed the regulatory conversation around GLP-1 drugs. It enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or above, but without diabetes. Participants received semaglutide 2.4mg or placebo weekly for a mean of 33 months. The primary endpoint, a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke, occurred 20% less frequently in the semaglutide group (6.5% vs 8.0%). That result crossed the threshold for statistical significance with a p-value below 0.001, leaving little room for debate about whether the effect was real.

What made SELECT even more significant was that the cardiovascular benefit appeared to be partly independent of weight loss. Participants in the lowest quartile of weight loss still showed cardiovascular improvement, though less than those who lost more weight. This suggested that semaglutide has direct anti-inflammatory and vascular protective effects beyond what you would expect from reduced body mass alone. The trial measured high-sensitivity C-reactive protein, a marker of systemic inflammation, and found a 38% reduction in the semaglutide group compared to placebo. That level of inflammation reduction is comparable to what statin therapy achieves, which is notable given how different the mechanisms are.